I have to agree with Lost Out. I think Acadia would be using data from Neuren's phase one to plan straight for phase two in whichever of the two diseases they choose. The only issue would be related to if Acadia wanted to look at a higher dose than what Neuren has tested at in which case they would likely need to check that in Phase 1.
I have to agree with Lost Out. I think Acadia would be using...
-
- There are more pages in this discussion • 735 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.59 |
Change
0.380(2.50%) |
Mkt cap ! $1.992B | |||
| Open | High | Low | Value | Volume |
| $15.51 | $15.82 | $15.46 | $11.26M | 722.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 696 | $15.59 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.67 | 6942 | 8 |
View Market Depth
| Last trade - 16.10pm 30/08/2024 (20 minute delay) ? |
| NEU (ASX) Chart |